13
Participants
Start Date
March 31, 2009
Primary Completion Date
December 31, 2014
Study Completion Date
January 31, 2015
CNTO 95 and avastin
"STAGE 1 (Dose escalation) Cohort # subjects CNTO 95 Bevacizumab~* 2 3-6 2.5 mg/kg IV Q3 weeks 7.5 mg/kg IV Q3 weeks~* 1 3-6 2.5 mg/kg IV Q3 weeks 15 mg/kg IV Q3 weeks~ 1. 3-6 5 mg/kg IV Q3weeks 15 mg/kg IV Q3 weeks~ 2. 3-6 10 mg/kg IV Q3 weeks 15 mg/kg IV Q3 weeks STAGE 2 (Biomarker) Cohort # subjects CNTO 95 Bevacizumab~ 3. 20 Recommended Phase II Dose Recommended Phase II Dose"
Duke University Medical Center, Durham
Collaborators (2)
Centocor, Inc.
INDUSTRY
Genentech, Inc.
INDUSTRY
Herbert Hurwitz, MD
OTHER